News | February 28, 2023
ENHERTU approved in China for patients with HER2 positive metastatic breast cancer treated withantiHER2-based regimens
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
In a bid to better leverage its clinical expertise and drive quality reporting across its centres, Thyrocare has added SigTuple’s AI100 to automate the microscopic review in its laboratories
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
Subscribe To Our Newsletter & Stay Updated
